Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications.
D006631:Amine Oxidase (Copper-Containing) / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology; D001786:Blood Glucose / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D003925:Diabetic Angiopathies / Q000209:etiology*; D003928:Diabetic Nephropathies / Q000209:etiology / Q000473:pathology; D017127:Glycation End Products, Advanced / Q000096:biosynthesis; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000209:etiology; D006984:Hypertrophy; D007328:Insulin / Q000737:chemistry; D007668:Kidney / Q000473:pathology; D008744:Methylamines; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D018716:Molecular Mimicry; D009765:Obesity / Q000209:etiology
D001786:Blood Glucose; D015815:Cell Adhesion Molecules; D017127:Glycation End Products, Advanced; D007328:Insulin; D008744:Methylamines; C027451:methylamine; C076668:AOC3 protein, human; D006631:Amine Oxidase (Copper-Containing)